Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 8/20 | 0.38 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994476 | 1.00 | FKBP1A (0.38) | FKBP1ADPP4DPP7FAAHALDH1A1 | |
| SCHEMBL994479 | 1.00 | FKBP1A (0.38) | FKBP1ADPP4DPP7FAAHALDH1A1 | |
| SCHEMBL997332 | 0.93 | FKBP1A (0.42) | FKBP1ADPP4DPP7ALDH1A1GAA | |
| SCHEMBL997334 | 0.93 | FKBP1A (0.42) | FKBP1ADPP4DPP7ALDH1A1GAA | |
| SCHEMBL997333 | 0.93 | FKBP1A (0.42) | FKBP1ADPP4DPP7ALDH1A1GAA | |
| SCHEMBL15107122 | 0.91 | FAAH (0.37) | FKBP1ADPP4DPP7FAAHALDH1A1 | |
| SCHEMBL10139494 | 0.87 | FKBP1A (0.43) | FKBP1AFAAHALDH1A1GAACTSL | |
| SCHEMBL17060193 | 0.87 | FKBP1A (0.39) | FKBP1ADPP4DPP7FAAHALDH1A1 | |
| SCHEMBL16611573 | 0.86 | FKBP1A (0.41) | FKBP1AALDH1A1GAAPDK1PDK2 | |
| SCHEMBL16611571 | 0.86 | FKBP1A (0.41) | FKBP1AALDH1A1GAAPDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178554-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2012-05-15 | — | — | US | disclosed |
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-06 | — | — | US | disclosed |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-09-01 | — | — | US | disclosed |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2011-01-27 | — | — | US | disclosed |
| US-7732610-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. (FR) | 2010-06-08 | — | — | US | disclosed |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | NOVEXEL (FR) | 2010-02-25 | — | — | US | disclosed |
| US-7638529-B2 | anti-bacterial agents; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen | AVENTIS PHARMA S.A. (FR) | 2009-12-29 | — | — | US | disclosed |
| US-7612087-B2 | Therapy for bacteria infections | NOVEXEL (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2009-08-27 | — | — | US | disclosed |
| US-7112592-B2 | topical bactericides and disinfectants for surgical instruments; staphylococci; coliform bacteria; 7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide; bridged bicyclic ureas or carbamates having bridgehead nitrogen | AVENTIS PHARMA S.A. (FR) | 2006-09-26 | — | — | US | disclosed |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-08-24 | — | — | US | disclosed |
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | AVENTIS PHARMA S.A. | 2006-03-02 | — | — | US | disclosed |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | AVENTIS PHARMA S.A. (FR) | 2005-01-27 | — | — | US | disclosed |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245254-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | FKBP1A 2156/4885DPP4 1091/4885DPP7 910/4885 |
| US-20110213147-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | FKBP1A 1382/4885DPP4 993/4885DPP7 1129/4885 |
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | FKBP1A 2156/4885DPP4 1091/4885DPP7 910/4885 |
| US-20060046995-A1 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, SDHB, SDHA | FKBP1A 1116/4885DPP4 1385/4885DPP7 1503/4885 |
| US-20060189652-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | FKBP1A 1382/4885DPP4 993/4885DPP7 1129/4885 |
| US-20050020572-A1 | Heterocyclic compounds as inhibitors of beta-lactamases | BACE1, GAA, CEL | FKBP1A 2156/4885DPP4 1091/4885DPP7 910/4885 |
| US-20110021772-A1 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents | NISCH, DDC, SDHA | FKBP1A 1382/4885DPP4 993/4885DPP7 1129/4885 |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | FKBP1A 2156/4885DPP4 1091/4885DPP7 910/4885 |
| US-20030199541-A1 | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | AZI2, NISCH, DCTPP1 | FKBP1A 979/4885DPP4 1204/4885DPP7 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.